The short version of NR1D1 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
A literary centre for many centuries, Turin began to attract writers only after the establishment of the court of the Dukes of Savoy. One of the most famous writers of the 17th century was Giambattista Marino, which in 1608 moved to the court of Charles Emmanuel I. Marino suffered an assassination attempt by a rival, Gaspare Murtola, and was later imprisoned for a year because of gossip that he had said and written against the duke. Perhaps, because of this, in 1615 Marino left Turin and moved to France. The main literary figures during the Baroque age in Turin were Emanuele Tesauro and Alessandro Tassoni. In the next century Torino hosted the poet Vittorio Alfieri from Asti for a while. The situation was very different in the 19th century, especially since the city became a point of reference for Italian unification and, subsequently, the capital of the Kingdom of Italy. Indeed, in those years Tommaseo, Settembrini and John Meadows resided in the city. A major literary and cultural woman of that time was Olimpia Savio. In the late 19th and early 20th centuries, Turin was home to writers such as Guido Gozzano, Edmondo De Amicis, Emilio Salgari and Dino Segre, the latter known by the pseudonym of Pitigrilli. Turin had a very important role in Italian literature after World War II. A major publishing house, Giulio Einaudi, published works by authors such as Cesare Pavese, Italo Calvino, Vitaliano Brancati, Primo Levi, Natalia Ginzburg, Fernanda Pivano, Beppe Fenoglio, Carlo Fruttero and Franco Lucentini.
== Implications == These properties of the genetic code make it more fault-tolerant for point mutations. For example, in theory, fourfold degenerate codons can tolerate any point mutation at the third position, although codon usage bias restricts this in practice in many organisms; twofold degenerate codons can withstand silence mutation rather than Missense or Nonsense point mutations at the third position. Since transition mutations (purine to purine or pyrimidine to pyrimidine mutations) are more likely than transversion (purine to pyrimidine or vice versa) mutations, the equivalence of purines or that of pyrimidines at twofold degenerate sites adds a further fault-tolerance.
== Background == Sugiol is a naturally occurring phenolic diterpenoid. Diterpenoids are a group of secondary metabolites with 20 carbons. Acyclic diterpenes are uncommon, due to the way that they are assembled, and include important molecules such as phytol. Sugiol has three six-membered rings, one of which is aromatic (ring C), and differs from ferruginol only by an addition of an oxo group bound to ring B. It may also be classified as an abietane, a class of tricyclic diterpenoids that share the same basic structure and are commonly found in the resin of conifers among other terrestrial plants. Aromatic abietanes that contain an aromatic carbon ring, such as sugiol and ferruginol, have exhibited a variety of interesting properties that have made them of high interest to the pharmacological community. Sugiol specifically has demonstrated anti-tumor, anti-microbial, antioxidant, and anti-viral activities. Sugiol has been shown to inhibit the oncogenic protein STAT3, which is constituently on in malignant tumors. Sugiol directly inhibits the enzyme transketolase, leading to a build up of reactive oxygen species (ROS) and stress-induced cell death. Reactive oxygen species are highly reactive, and can damage cellular mechanisms by oxidizing critical molecules. Sugiol downregulates inflammatory genes such as NF-κB, COX-2, TNF-alpha, IL-1beta, and IL-6. Sugiol prevents virus triggered cytopathic effects as a result of H1N1 in MDCK cells for up to 72 hours.
Pro-inflammatory myeloid cells along with production of the pro-inflammatory cytokines interleukin-1α (IL-1α), interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor α (TNF-α) have been found to increase with age in rodents and humans. This is part of "inflammaging". Activation of these myeloid cells and consequent elevation in cytokine levels have been found to be suppressed by thymulin via inhibition of NF-κB signaling. Thymulin levels decrease with age.
In commenting on humanity's evolution from an ancient primate ancestor, Jung wrote: "We keep forgetting that we are primates and that we have to make allowances for these primitive layers in our psyche." Jung also developed the notion of different evolutionary layers in the psyche in his discussion of fossil hominins such as Pithecanthropus (Homo erectus). As he writes:
Sources: en.wikipedia.org
Chloroplasts, like other endosymbiotic organelles, contain a genome separate from that in the cell nucleus. The existence of chloroplast DNA (cpDNA) was identified biochemically in 1959, and confirmed by electron microscopy in 1962. The discoveries that the chloroplast contains ribosomes and performs protein synthesis revealed that the chloroplast is genetically semi-autonomous. Chloroplast DNA was first sequenced in 1986. Since then, hundreds of chloroplast genomes from various species have been sequenced, but they are mostly those of land plants and green algae—glaucophytes, red algae, and other algal groups are extremely underrepresented, potentially introducing some bias in views of "typical" chloroplast DNA structure and content.
==== Narration styles ==== Voice-over narrator The traditional style for narration is to have a dedicated narrator read a script which is dubbed onto the audio track. The narrator never appears on camera and may not know the subject matter or be involved in writing the script.
== See also == All pages with titles containing Link Linc (disambiguation) Lincs (disambiguation) Linker (disambiguation) Linq (disambiguation) Linx (disambiguation) Lynx (disambiguation) Microsoft Lync Linkt, road tolling brand in Australia
Users have reported that mephedrone causes euphoria, stimulation, an enhanced appreciation for music, an elevated mood, decreased hostility, improved mental function and mild sexual stimulation; these effects are similar to the effects of cocaine, amphetamines and MDMA, and last different lengths of time depending on the way the drug is taken. Of 70 Dutch users of mephedrone, 58 described it as an overall pleasant experience, and 12 described it as an unpleasant experience. In a survey of UK users who had previously taken cocaine, most users found it produced a better-quality and longer-lasting high and was less addictive. The users were also asked to compare the "risk", and they answered that it was equal. A study of users in Northern Ireland found they did not equate the fact that mephedrone was legal with it being safe to use. This was contrary to another study in New Zealand, where users of benzylpiperazine thought that because it was legal, it was safe.
Sources: en.wikipedia.org
146C → 147N + e− + νe By emitting a beta particle (an electron, e−) and an electron antineutrino (νe), one of the neutrons in the 14C nucleus changes to a proton and the 14C nucleus reverts to the stable (non-radioactive) isotope 14N.
At a White House press briefing on September 22, 2025, President Trump, joined by Kennedy and other senior officials, said the FDA would revise drug labels to discourage the use of acetaminophen (sold under the brand name Tylenol) during pregnancy, citing a possible link to autism. Medical and public health experts disputed the claim. Steven J. Fleischman, president of the American College of Obstetricians and Gynecologists, wrote, "It is highly unsettling that our federal health agencies are willing to make an announcement that will affect the health and well-being of millions of people without the backing of reliable data." A month later, on October 29, Kennedy retracted his statements from the press conference, stating that acetaminophen use in pregnancy is not linked to autism. On November 10, 2025, in response to President Trump's false claim, a 2025 British Medical Journal umbrella review was fast-tracked and confirmed no convincing evidence that paracetamol (acetaminophen) use during pregnancy increases the risk of autism spectrum disorder (ASD) or attention deficit hyperactivity disorder (ADHD) in children. The review, led by researchers at the University of Liverpool, analysed nine systematic reviews covering 40 observational studies and concluded that any apparent associations were likely due to family genetics, maternal health, or other shared factors rather than the drug itself.
Brent ( ) is a borough in west and north-west London, England; it forms part of Outer London. It is known for landmarks such as Wembley Stadium, the Swaminarayan Temple and the Kiln Theatre. It also contains the Welsh Harp reservoir and the Park Royal commercial estate. The local authority is Brent London Borough Council. Brent's population was estimated to be 353,000 as of 2024. Major districts are Kenton, Kilburn, Willesden, Wembley and Harlesden, with sub-districts Stonebridge, Kingsbury, Kensal Green, Neasden, and Queen's Park. Brent has a mixture of residential, industrial and commercial land. It includes many districts of inner-city character in the east and a more distinct suburban character in the west, part of which formed part of the early 20th century Metroland developments.
In 2017, the U.S. Food and Drug Administration (FDA) approved L-glutamine oral powder, marketed as Endari, to reduce severe complications of sickle cell disease in people aged five years and older with the disorder. The safety and efficacy of L-glutamine oral powder were studied in a randomized trial of subjects ages five to 58 years old with sickle cell disease who had two or more painful crises within the 12 months prior to enrollment in the trial. Subjects were assigned randomly to treatment with L-glutamine oral powder or placebo, and the effect of treatment was evaluated over 48 weeks. Subjects who were treated with L-glutamine oral powder experienced fewer hospital visits for pain treated with a parenterally administered narcotic or ketorolac (sickle cell crises), on average, compared to subjects who received a placebo (median 3 vs. median 4), fewer hospitalizations for sickle cell pain (median 2 vs. median 3), and fewer days in the hospital (median 6.5 days vs. median 11 days). Subjects who received L-glutamine oral powder also had fewer occurrences of acute chest syndrome (a life-threatening complication of sickle cell disease) compared with patients who received a placebo (8.6 percent vs. 23.1 percent). Common side effects of L-glutamine oral powder include constipation, nausea, headache, abdominal pain, cough, pain in the extremities, back pain and chest pain. L-glutamine oral powder received orphan drug designation. The FDA granted the approval of Endari to Emmaus Medical Inc.
According to López, the MTC benefited Chinese companies, principally the state-owned construction company China Civil Engineering Construction Corporation, which partnered with the company INIP Ingeniería Integración de Proyectos, the latter led by Roberto Aguilar Quispe, forming a partnership that won contracts between August 2021 and January 2022 worth 581 million soles. In August 2025, Attorney General Delia Espinoza presented a constitutional complaint before congress against Castillo and 24 congressmen, including those known as "Los Niños", for steering bids in favor of Chinese companies belonging to the so-called "Dragon Club".
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.